KRAS, a frequently mutated oncogenic protein in human cancers, plays a pivotal role in regulating MYC and mTOR activity through RAF-MEK-ERK and PI3K-AKT pathways, respectively [129, 130] (Fig. 2c). Here, MYC is linked to cancer.